GlassScriptPhysician profile
Derrick A Randolph
NPI 1760882690
$2,113.31
in general payments reported to CMS, 2019-2025
28 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $599 · 2023: $479 · 2024: $232 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.41 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $321.50 | 2021-2024 | |
| Glaxosmithkline, LLC. | $282.89 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $181.06 | 2021-2025 | Verquvo |
| Paratek Pharmaceuticals, INC. | $162.68 | 2023-2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $102.85 | 2022-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $87.72 | 2023-2024 | Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $69.26 | 2022-2023 | |
| Genentech USA, INC. | $66.13 | 2021 | |
| Lilly USA, LLC | $44.70 | 2022 | |
| Abbott Laboratories | $36.38 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.19 | 2022-2024 | Cycloset |
| Currax Pharmaceuticals LLC | $29.76 | 2021-2022 | |
| Braeburn INC. | $25.38 | 2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $22.94 | 2025 | Fanapt |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $21.13 | 2021 | |
| Csl Behring | $20.89 | 2024 | Haegarda |
| Exact Sciences Corporation | $19.43 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $17.96 | 2024 | |
| Amgen INC. | $17.48 | 2024 | Repatha, Otezla |
| Daiichi Sankyo INC. | $17.33 | 2021 | |
| Intra-Sana Laboratories | $15.50 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.37 | 2025 | Rexulti |
| Ibsa Pharma INC. | $14.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.79 | 2022 | |
| Astellas Pharma US INC | $12.50 | 2021 | |
| Eisai INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.